Wczytywanie spółki
LLYELI Lilly And Company1,35T USDA+Just reported
From AbbVie's results release of 30 października 2026; its quarterly report has since been filed.
Actual
17,4B USD
+10% y/y
+2,4% q/q
Guided
—
No guide given
Actual
2,37 USD
+17% q/q
Guided
—
No guide given
Actual
6,27B USD
+229% y/y
-2,6% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Udziały w przychodach to szacunki za fiscal year 2025, high confidence, a nie dane z raportu złożonego do regulatora.
Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.
Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.
Pełne sprawozdania finansowe →
AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.
Zbudowane z własnych raportów spółki AbbVie Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
294,49 USD-0,1%zamknięcie 12 lis
Dane do 30 września 2026, z raportu 10-Q złożonego 3 listopada 2026
AbbVie researches, develops and sells medicines and aesthetic treatments for immune diseases, neurological conditions, cancers and other health needs.
Grade B+
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 41 kwartałów historii ocen spółki AbbVie Inc.. Pozostałe 39 sięgają do listopad 2016.
